News Headlines

  1. RedHill Biopharma Announces Final Results From Phase II Study With BEKINDA® For IBS-D
    1/16/2018

    RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases and cancer, today announced top-line final results1 from the Phase II clinical study with BEKINDA®12 mg (RHB-102)2 for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).

  2. Syneos Health Releases 2018 Commercial Trends Forecast
    1/10/2018

    Syneos Health, the only fully integrated biopharmaceutical solutions organization combining a CRO and a CCO (Contract Commercial Organization), today released its inaugural Commercial Trends Forecast.

  3. Atara Biotherapeutics Announces FDA Clearance To Proceed With Enrollment At U.S. Sites For Ongoing Global Phase 1 Clinical Study To Evaluate ATA188 In Patients With Progressive Or Relapsing-Remitting Multiple Sclerosis
    1/10/2018

    Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that it received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to proceed with patient enrollment at U.S. sites for its ongoing global Phase 1 clinical study to evaluate ATA188 in patients with progressive or relapsing-remitting multiple sclerosis (MS).

  4. New Clinical Study May Be The World's First Cure For Alzheimer's Disease
    1/10/2018

    Libella Gene Therapeutics LLC will conduct an outside the United States(OUS) clinical trial in Cartagena, Colombia, using gene therapy to reverse age-related diseases, starting with Alzheimer's.

  5. Flexion Therapeutics Announces Initial Data From Clinical Trial Evaluating Repeat Administration Of ZILRETTA (Triamcinolone Acetonide Extended-Release Injectable Suspension)
    1/9/2018

    Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced initial findings from its ongoing Phase 3b, open-label study to evaluate the repeat administration of ZILRETTATM (triamcinolone acetonide extended-release injectable suspension) in patients with osteoarthritis (OA) of the knee. 

  6. eClinical Data Volume And Diversity Pose Increasing Challenges And Delays, According To The Tufts Center For The Study Of Drug Development
    1/9/2018

    The growing volume of data collected in clinical trials is contributing to longer development times and posing technical and integration challenges to clinical data management staff, according to a recently completed analysis by the Tufts Center for the Study of Drug Development.

  7. Sanofi And Alnylam Enter Into Strategic Restructuring Of RNAi Therapeutics Rare Disease Alliance
    1/7/2018

    Sanofi and Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development and commercialization of certain products for the treatment of rare genetic diseases.

  8. Akcea Initiates Phase 2b Study Of AKCEA-APOCIII-LRx In Patients With Hypertriglyceridemia And Established Cardiovascular Disease
    1/5/2018

    Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced the initiation of a Phase 2b clinical study of AKCEA-APOCIII-LRx in patients with hypertriglyceridemia and established cardiovascular disease (CVD).

  9. Inspire And Antidote Launch End-To-End Clinical Trial Recruitment Solution To Accelerate Medical Research
    1/5/2018

    Inspire, the leading healthcare social network, and Antidote, a digital health company that connects patients with research, announced a strategic collaboration today that will provide an unparalleled end-to-end patient recruitment model to pharmaceutical companies and CROs.

  10. INC Research/Inventiv Health Becomes Syneos Health™
    1/4/2018

    INC Research/inVentiv Health recently announced it has changed its brand identity to Syneos Health, Inc., effective January 4, 2018. More than 21,000 of the top minds in clinical and commercial development are now united under this singular brand, signifying the culmination of a thoughtful merger combining industry-leading Contract Research Organization (CRO) and Contract Commercial Organization (CCO) capabilities.